RETN and myeloid sarcoma: Compared to patients without MS, patients with MS had higher serum resistin levels (7.1 ± 7.0 vs. 5.8 ± 3.8 ng/mL, p = 0.036) and lower serum adiponectin levels (5.8 ± 4.7 vs. 7.5 ± 5.7 μg/mL, p = 0.002).